The spindle assembly checkpoint (SAC) is essential in mammalian mitosis to ensure the equal segregation of sister chromatids 1,2 . The SAC generates a mitotic checkpoint complex (MCC) to prevent the anaphase-promoting complex/cyclosome (APC/C) from targeting key mitotic regulators for destruction until all of the chromosomes have attached to the mitotic apparatus 1,3,4 . A single unattached kinetochore can delay anaphase for several hours 5 , but how it is able to block the APC/C throughout the cell is not understood. Present concepts of the SAC posit that either it exhibits an all-or-nothing response 6 or there is a minimum threshold sufficient to block the APC/C (ref. 7). Here, we have used gene targeting to measure SAC activity, and find that it does not have an all-or-nothing response. Instead, the strength of the SAC depends on the amount of MAD2 recruited to kinetochores and on the amount of MCC formed. Furthermore, we show that different drugs activate the SAC to different extents, which may be relevant to their efficacy in chemotherapy.
could be degraded when the SAC was active because it bound to CDC20 in competition with the MCC (ref. 17) . We thought that this should provide an assay for SAC activity, that is, the rate of MCC production, because the rate of cyclin A2 degradation should be determined by competition for CDC20 with the MCC. To test this, we needed to measure precisely the prometaphase destruction of cyclin A2 (refs 18-20) . Therefore, we used recombinant adenovirus-associated virus (rAAV)-mediated gene targeting to introduce the open reading frame (ORF) of yellow fluorescent protein (Venus) into the last exon of one allele of the CCNA2 (cyclin A2) gene in hTert-RPE1 cells (RPE1; retinal pigment epithelial; Fig. 1a and Supplementary Fig. S1a,b ). (Note that this fusion generated a functional protein 18 .) We chose RPE1 cells because they have a normal diploid karyotype, are not transformed and exhibit little cell death when arrested in mitosis; tagging the endogenous cyclin A2 protein in RPE1 cells avoided the complications of mosaic protein levels in the cell population produced by ectopic expression. Immunoblotting analysis showed that cells expressed the fusion protein to the same level as the untagged protein ( Fig. 1b ). Time-lapse microscopy showed that individual cells in the population had very similar kinetics of cyclin-A2-Venus degradation and mitotic progression ( Supplementary Fig. S1c and Video S1).
Our hypothesis predicted that the rate of cyclin A2 degradation should be accelerated when we eliminated the production of MCC, either by depleting MAD2, or by inhibiting MPS1, an essential SAC kinase. Conversely, maintaining the SAC, for example by, treating cells with the Eg5 spindle motor poison di-methyl anastron (DMA), should reduce the rate of cyclin A2 degradation. Both of these predictions were verified ( Supplementary Fig. S1d ), from which we concluded that the rate of degradation of cyclin-A2-Venus could serve as a quantitative assay for SAC activity.
Taxanes and vinca alkaloids are effective anti-cancer agents, possibly through their ability to activate the SAC (refs 21,22) , so understanding how such compounds affect the SAC could be therapeutically valuable. To investigate this we treated RPE1 CCNA2 Venus/+ cells with Taxol, DMA or nocodazole and found that although all three drugs delayed (a) Venus ORF targeting into the human CCNA2 locus by rAAV-mediated homologous recombination. The rAAV vector contains the coding sequence of Venus, which was inserted between two gene-specific homology arms to replace the STOP codon at the junction between non-coding (white square) and coding (black square) regions in exon 8 and two inverted terminal repeats (L-ITR, R-ITR; red rectangles). Integrants were selected by fluorescence-activated cell sorting (FACS). (b) Western blot analysis of parental RPE1 and a cyclin-A2-Venus clone. Cell lysates were probed with anti-cyclin A2 (left panel) and anti-GFP (right panel) antibodies. Note the two forms of cyclin A2 in the cyclin-A2-Venus clone (the upper one uniquely recognized by the anti-GFP antibody). Relative molecular mass markers are shown on the left. (c,d) Single-cell cyclin-A2-Venus destruction assays of asynchronously growing RPE1 cyclin-A2-Venus cells treated with nocodazole (n = 15 cells), Taxol (n = 12 cells) or DMA (n = 12 cells; c) or different concentrations of AZ3146 in the presence of 10 µM DMA (n = 15 cells for all conditions except 5 µM AZ3146, where n = 11 cells; d). Images were acquired at 3-5 min intervals and the total cell fluorescence was quantified. Fluorescence intensities were normalized to the level at NEBD. Error bars indicate s.d. and are representative of at least two independent experiments. The time to reach half-maximum fluorescence after NEBD was used for statistical tests.
cells in mitosis, the rate of cyclin-A2-Venus destruction was faster in Taxol than in nocodazole or DMA (Fig. 1c) ; therefore, different microtubule poisons generated different levels of SAC activity. Furthermore, when we inhibited Mps1, the rate of cyclin A2 degradation increased and the mitotic delay decreased in proportion to the concentration of the inhibitor (AZ3146) ( Fig. 1d and Supplementary Fig. S1e ), showing that partially inhibiting Mps1 reduced the strength of the SAC. Our results indicated that different spindle poisons activated the SAC to different extents, which prompted us to investigate whether this determined their ability to arrest cells in mitosis. Work from a number of laboratories supports the hypothesis that the extent to which cells delay in mitosis depends on two antagonistic pathways, whereby a gradual increase in activity of a pro-apoptosis pathway is counteracted by the slow degradation of cyclin B1 and securin, and consequent mitotic exit (called mitotic slippage) 21, 23, 24 . The extent of mitotic slippage varies between individual cells and between cell lines, and in response to different drugs 21 . We postulated that the rate of mitotic slippage could be governed by the strength of the SAC generated by different drug treatments.
Mitotic slippage had previously been measured by the degradation of ectopic cyclin B1 (refs 21,23), but as altering the level of cyclin-B1-CDK1 activity affected the fate of cells in mitosis 21 , we chose to assay the destruction of endogenous cyclin B1 by using rAAV-mediated gene targeting to fuse exon 9 of the CCNB1 (cyclin B1) locus to the ORF of Venus in RPE1 cells ( Fig. 2a,b and Supplementary  Fig. S2a -c), which produces a functional fusion protein 25 . Just as for cyclin-A2-Venus, the cyclin-B1-Venus protein accumulated and was destroyed with similar kinetics to the untagged endogenous protein ( Supplementary Fig. S2d,e ). Quantitative fluorescence imaging showed that cyclin-B1-Venus destruction began at metaphase ( Supplementary  Fig. S2f ; control and Video S2) and was regulated by the SAC ( Supplementary Fig. S2f ; reversine and nocodazole).
We treated RPE1 CCNB1 Venus/+ cells with various microtubule poisons and assayed them by time-lapse fluorescence microscopy. We Figure 2 Different spindle poisons activate the SAC to different extents. (a) Venus ORF targeting into the human CCNB1 locus by rAAV-mediated homologous recombination. The rAAV vector contains both the coding sequence of Venus and a G418 resistance cassette (flanked by loxP sites, red triangles), which were inserted between two gene-specific homology arms to replace the STOP codon at the junction between non-coding (white square) and coding (black square) regions in exon 9 and two inverted terminal repeats (L-ITR, R-ITR; red rectangles). Integrants were selected by survival in G418-containing medium. reasoned that assaying cyclin-B1-Venus levels over time in cells blocked in mitosis should provide a measure of the effectiveness with which the SAC could repress APC/C activity because weaker SAC activity should result in a higher rate of cyclin B1 destruction. In agreement with other studies 21, 26 , we found that Taxol-treated cells spent less time in mitosis (555.9 ± 345.6 min) when compared with cells treated with DMA (1,101 ± 410.1 min) or nocodazole (1,481 ± 529 min; Fig. 2c ), even though DMA produces similar kinetochore attachment defects to Taxol 27, 28 . The reason for this discrepancy was different rates of proteolysis: cyclin-B1-Venus levels fell faster in Taxol-treated cells when compared with DMA, and faster in DMA than in nocodazole (0.33 µM; Fig. 2d ). This was not caused by a direct effect of the drugs on APC/C activity because when MAD2 was depleted by short interfering RNA (siRNA), cyclin-B1-Venus was degraded with the same kinetics in the different drugs ( Fig. 2e ). Instead, the kinetics of cyclin-B1-Venus destruction correlated with the strength of the checkpoint we had previously measured using the disappearance of cyclin-A2-Venus. The average slope of cyclin-B1-Venus destruction in different drug treatments correlated inversely (r 2 = 0.9482) with the time cells spent in mitosis ( Fig. 2f ), indicating that the length of mitotic arrest probably depended on how effectively the APC/C was inhibited by the SAC. To test this further, we used serial dilutions of the MPS1 inhibitor AZ3146 in cells treated with 0.33 µM nocodazole, and found that a progressive increase in AZ3146 concentration caused an increase in the rate of cyclin-B1-Venus destruction (Fig. 2g ), and, as previously observed, a reduced mitotic delay 29 ( Supplementary Fig. S2g ).
The differences in cyclin A2 and cyclin B1 degradation rates in response to different drugs indicated that the strength of the SAC was variable rather than all-or-nothing. To understand how the strength of the SAC could vary we needed a quantitative measure of the kinetochores that generated a SAC signal. To achieve this we used gene targeting to fuse the Venus ORF to the 5 of exon 1 of one allele of the MAD2L1 gene. We tagged MAD2 at its amino terminus because a GFP-MAD2 fusion protein had previously been demonstrated to be functional in Drosophila 30 . Immunoblotting showed that Venus-MAD2 was expressed at a similar level to untagged MAD2 (Fig. 3a,b and Supplementary Fig. S3a ,b) and high-resolution imaging confirmed that it was an accurate marker for unattached kinetochores ( Supplementary Fig. S3c,d and Video S3).
Treating RPE1 cells with Taxol, DMA or nocodazole gave the expected spindle and kinetochore phenotypes ( Fig. 3c ): Taxoltreated cells exhibited collapsed spindles with hyperstable/elongated microtubules; DMA-treated cells had monopolar spindles; nocodazole (0.33 µM)-treated cells lacked spindle microtubules but contained clustered kinetochore microtubules. Under these conditions, we found that more kinetochores recruited Venus-MAD2 in cells treated with nocodazole (25.29 ± 9.46) than with DMA (10.62 ± 6.42) or Taxol (4.84 ± 3.14) ( Fig. 3d,e ). These values were comparable to immunofluorescence measurements on the parental RPE1 cell line using an anti-MAD2 antibody ( Supplementary Fig. S3d ); therefore, Venus-MAD2 was an accurate marker for MAD2 recruitment to improperly attached kinetochores.
In addition to containing more MAD2-positive kinetochores, in nocodazole-treated cells the individual kinetochores recruited more Venus-MAD2 molecules (estimated as 114.0 ± 60.4) than in cells treated with Taxol (77.9 ± 30.1) or DMA (65 ± 25.0) ( Fig. 3f and Supplementary Fig. S3e -j). These differences in protein numbers were not attributable to variations in the size of kinetochores because there was no correlation between the intensity of kinetochore-bound Venus-MAD2 and HEC1, a stable kinetochore protein ( Fig. 3g ). In contrast, the amounts of MAD2 recruited to improperly attached kinetochores inversely correlated with kinetochore microtubule abundance. The kinetochores in nocodazole-treated cells are mostly unattached (at 0.33 µM), whereas kinetochores do attach to microtubules in Taxol-and DMA-treated cells but these attachments are destabilized by the error-correction machinery, thereby generating fluctuating numbers of unattached kinetochores.
The combined numbers of Venus-MAD2 molecules and MAD2 foci per cell strongly correlated (r 2 = 0.9123) with the extent of the mitotic delay in each drug treatment ( Fig. 3h ). This indicated that the recruitment of MAD2 to kinetochores was important for the strength of the SAC. To test this, we assayed the effect on the SAC of depleting MAD2 to different extents by sub-optimal siRNA treatment in RPE1 hMAD2L1 Venus/+ cells ( Fig. 4a ). Our endogenous targeting allowed us to determine the extent of MAD2 depletion in individual cells by measuring the total Venus-MAD2 fluorescence. Reducing total cellular MAD2 to ∼30 to 40% of its normal level caused a graded reduction in the length of the checkpoint arrest ( Fig. 4b) , showing that under the same conditions, the amount of MAD2 did indeed influence the strength of the SAC. It was notable that once MAD2 was depleted to below 30-40% of the normal level the checkpoint was no longer functional and cells quickly exited mitosis (Fig. 4b,c ). This high threshold amount of MAD2 required for the checkpoint surprised us because we had previously found that most MAD2 was free in the cell 12, 31 . The integrated Venus-MAD2 fluorescence at kinetochores after nuclear envelope breakdown (NEBD) largely mirrored the total amount of Venus-MAD2 ( Fig. 4d ) and correlated with the duration of the mitotic arrest ( Fig. 4e ). This supported the idea that the amount of MAD2 recruited to kinetochores might determine the strength of the SAC, an idea that was strongly reinforced when we focused on cells that contained very similar amounts of total Venus-MAD2. We observed that the SAC was always stronger in those cells that recruited more Venus-MAD2 to kinetochores ( Fig. 4c-e ). Thus, we conclude that the amount of MAD2 recruited to kinetochores is a crucial determinant of the strength of the SAC.
The molecular endpoint of the SAC is the incorporation of CDC20 into the MCC (refs 4,10,11,32,33); therefore, we examined the abundance of MCC components (MAD2, BUBR1 and CDC20) bound to the APC/C and CDC20 in extracts of mitotic cells treated with different drugs (Fig. 5a ). This showed that CDC20 bound to more MAD2 in cells treated with nocodazole when compared with DMA, and more in DMA when compared with Taxol ( Fig. 5b,d) , whereas the amount of BUBR1 bound to CDC20 remained unchanged ( Fig. 5b,d ). We interpreted this as a change in the ratio of MCC complexes with and without MAD2, because we, and others, had previously found that MAD2 was substoichiometric to BUBR1 and CDC20 in the MCC (refs 10,12,13) . To test this, we compared MCC that was free or bound to the APC/C by immunoprecipitation ( Fig. 5a ) and size exclusion chromatography ( Supplementary Fig. S4a-c ). This indicated that, at the molecular level, the strength of the SAC could be determined by the amount of MCC generated per unit time, and thus its concentration in the cell, and that binding to the APC/C was limiting. Whereas the levels In c-e, cells that have similar total MAD2 levels were assigned matching numbers and the green colour highlights the cell in each match that has more Venus-MAD2 at kinetochores, compared with the red cell, which has less. Note that in all cases this resulted in different mitotic arrests (green, stronger checkpoint; red, weaker checkpoint). n > 50 cells. Representative of two independent experiments.
of APC/C-bound MCC proteins remained approximately the same in all drug treatments, the levels bound to non-APC/C-associated CDC20 increased as the strength of the SAC increased. The strongest effect was seen in nocodazole-treated cells, where BUBR1 accumulated ∼2-fold and MAD2 ∼3-fold (Fig. 5b,e and Supplementary Fig. S4b,c) .
To test this further, we arrested cells with nocodazole, DMA or Taxol, then inactivated the SAC with AZ3146 and monitored the kinetics of mitotic exit, predicting that cells with more MCC should take longer to exit mitosis because more time would be required for all of the MCC to disassemble. In agreement with this, the rate at which cells exited mitosis was inversely proportional to the amount of the MCC in the cells: Taxol-treated cells exited faster (t 1/2 = 6.68 ± 0.33 min) than DMA-treated cells (t 1/2 = 9.00 ± 0.19 min), and DMA-treated cells faster than nocodazole-treated cells (t 1/2 = 30.69 ± 0.39 min) (Fig. 5g,h) . Note that each half-life value was corrected by subtracting the minimum half-life for mitotic exit in the presence of a CDK1 inhibitor RO3306 (Fig. 5h, inset) . Although some of these differences might be attributed to the error-correction role of MPS1 (refs 29,34-36) , because cells satisfy the checkpoint quicker in Taxol or DMA when compared with nocodazole, this would make only a minor contribution because AZ3146 reduced the mitotic delay by 95.4% for Taxol, 94.8% for DMA and 91.9% for nocodazole (Figs 2c and 5i) , a difference of only 3.5% between error-correction conditions and nocodazole.
Together, our data support a model in which the SAC does not behave as an all-or-nothing toggle switch. Instead, the SAC is like a rheostat: it can be activated to different levels, and thereby inhibit the APC/C to different extents, which dictates the length of a mitotic delay. The strength of the SAC depends on the number of signalling centres (kinetochores), and critically on the amount of MAD2 recruited to kinetochores, which probably determines the rate of MCC production ( Supplementary Fig. S5a ).
Our findings have implications for the control of mitosis. At the start of an open mitosis most kinetochores are unattached, which would produce a pulse of MCC to inhibit the APC/C. As chromosome attachments are established, the declining numbers of unattached kinetochores generate sufficient inhibitory complex to prevent premature anaphase, but because the MCC is constantly disassembled this will reduce the amount of MCC ( Supplementary  Fig. S5b ). The progressive reduction in MCC level, allied with the role of protein phosphatases in chromosome attachment 37 Relative binding to CDC20 (Taxol = 1)
Relative binding to CDC20 (Taxol = 1)
A P C Supplementary Fig. S6. silencing 38, 39 , would contribute to the efficient coupling between correct bipolar attachment of chromosomes and rapid anaphase onset ( Supplementary Fig. S5c and unperturbed) . In drug-induced arrests, MCC production will be continuous, at a rate depending on the ability of the drug to prevent correct kinetochore attachments ( Supplementary  Fig. S5c ; Taxol, DMA and nocodazole). This may explain why depleting p31Comet 13, 31, 40, 41 and APC15 (refs 31), both negative regulators of the SAC, has only relatively mild effects in normally dividing cells (small pulse of MCC), whereas they are strongly additive in drug-induced arrests (continuous production of MCC). Our finding that the SAC can be activated to different degrees by different drugs has implications for anti-cancer therapies based on microtubule poisons and microtubule motor inhibitors 16 . Moreover, our observation that there is a critical threshold of MAD2 required for a functional SAC may be an important clue to the mechanism by which the MCC is generated and inhibits the APC/C, and for the observation that MAD2 is a haploinsufficient tumour suppressor 42 .
METHODS

Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb2855 METHODS Plasmids and cloning. Homology arms to human cyclin A2 (CCNA2), human cyclin B1 (CCNB1) and human MAD2 (MAD2L1) genes were amplified from h-TERT-RPE1 genomic DNA using High-Fidelity polymerase (Roche). Targeting constructs were assembled in a NotI-digested pAAV vector by 4-piece DNA ligation with the coding sequence of a fluorescent protein fused or not with a neomycin-resistant cassette from the pNX vector 23 and two homology arms. Clones were screened by colony PCR and restriction enzyme digestion. All constructs were sequenced to ensure their integrity.
Production of rAAV particles and cell infections.
All rAAV preparations were made as previously published 43 . For FACS selection, h-TERT-RPE1 cells were seeded on a single T75 flask 24 h before infection. The next day, cells were washed twice in PBS+Mg+Ca (100 mg l −1 ) and infected with 3 ml of viral supernatant complemented with 7 ml of DMEM/F12 medium (Sigma). After 48 h, cells were washed twice in PBS+Mg+Ca, trypsinized, seeded into two 140 mm tissue culture dishes and allowed to grow until 80% confluence was reached. Cells were split into 4 × 140 mm tissue culture dishes and treated the next morning with 5 mM thymidine for 24 h. Cells were then washed twice in PBS+Mg+Ca and released into fresh medium for 4-6 h to enrich for cells in G2 phase.
Culture conditions and treatments. Normal RPE1 and knock-in cell lines were cultured in F12/DMEM (Sigma) medium supplemented with GlutaMAX (Invitrogen), 10% FBS (Gibco), 0.348% sodium bicarbonate, penicillin (100 U ml −1 ), streptomycin (100 µg ml −1 ) and Fungizone (0.5 µg ml −1 ). Cells were maintained in a 37 • C incubator with 5% CO 2 and cultured for a minimum of 48 h before experiments and or drug treatments. For experiments on populations of cells arrested in mitosis (biochemistry, kinetochore and molecule numbers counts), cells were treated for 12-16 h with Taxol (0.116 µM), DMA (10 µM) and nocodazole (0.33 µM). For other imaging experiments, cells were seeded either on 96-well plates (µClear, Greiner) or 8-well chamber slides (µSlide, ibidi) and drugs were added directly into the imaging medium before acquisition unless otherwise stated. For RNA interference, RPE1 cells were transfected with Lipofectamine RNAiMAX (Invitrogen) and MAD2 siRNA oligonucleotide A MoFlo high-speed cell sorter (Beckman Coulter) was used to isolate cells by fluorescence. Cells were analysed for forward and side scatter to eliminate debris, and doublet discrimination to ensure that only single cells were sorted. ToPro-3 (Molecular Probes, Invitrogen) (excitation at 633 nm, detection at 670 nm) was added to the cells to exclude dead cells. Venus fluorescence (excitation at 488 nm) was detected using a 530/30 nm filter and to distinguish between autofluorescent cells and Venus-positive cells, the 530/30 nm channel was selected against the 580/40 filter that showed autofluorescent cells at a 45 degree angle. Venus-positive cells formed a discrete population that was dimmer than the autofluorescent cells on the 580/40 axis. Negative cells were used to set the voltages for all channels and to set the positive gate. Venus-positive cells were individually sorted into single wells of a 96-well plate filled with conditioned medium.
Diagnostic PCR and western blot analysis. Neomycin-resistant clones and
clones retained following microscopy screens were subjected to diagnostic PCR analysis using genomic DNA extracted from cells in 96-and 24-well plates, respectively. The following sequences of oligonucleotides were used for diagnostic PCR: 5 cyclin A2: 5 -TGCTCCAACAGTAAATCAG-3 , 3 cyclin A2: 5 -CACCAGCAATGCCAAAG-3 , 5 cyclin B1: 5 -TTCACCGTGTTAGCCAGGAT-3 , For immunoblot analyses, cells were typically cultured in 6-well dishes to 70% confluence, washed in PBS and lysed in 100 µl sample buffer. Ten microlitres of the extracts was loaded and run on a 4-12% NuPAGE gel (Invitrogen) and transferred to PVDF membrane before immunoblotting. The following antibodies were used at the indicated dilution: CCNA2 (monoclonal antibody raised against cyclin A2, 1:1,000), CCNB1 (monoclonal antibody, clone GNS-1, 1:2,000, BD Pharmingen), MAD2 (polyclonal antibody, 1:1,000; Bethyl Laboratories) BUBR1 (polyclonal antibody A300-386A, 1:1,000, Bethyl Laboratories), BUB3 (polyclonal antibody, 1:1,000, BD Transduction Laboratories), CDC20 (polyclonal antibody, A301-180A, 1:1,000; Bethyl Laboratories), APC3 (monoclonal antibody, clone 35/CDC27, 1:1,000, BD Transduction Laboratories), APC4 (monoclonal antibody raised against a carboxy-terminal peptide, 1:1,000), anti-GFP (monoclonal antibody, clone JL-8, 1:1,000; Clontech), TUBB (betatubulin) (polyclonal antibody, ab6046, 1:200, Abcam), HEC1 (monoclonal antibody, clone 9G3, 1:500, Abcam). Antibodies were detected and analysed using the LiCOR Odyssey system according to the manufacturer's instructions (LI-COR Biosciences).
Immunoprecipitations and size-exclusion chromatography. Cells were lysed for 30 min on ice in lysis buffer (PBS, 0.5% NP40, 0.2 µM microcystin and Roche complete protease inhibitor cocktail) and lysates were cleared by centrifugation (15 min, 16,100g ) . Immunoprecipitations were carried out with antibodies convalently coupled to protein G Dynabeads (Invitrogen) with 500 µg of protein extracts per condition. Beads were washed three times with lysis buffer and protein complexes were eluted using LDS-sample buffer (Invitrogen). Size-exclusion chromatography was carried out on a Superose 6 PC 3.2/30 column (GE Healthcare) as previously described 37 .
Microscopy. Primary screens were conducted 7-10 days after cell sorting. Each 96-well plate was scanned using an ImageXpress micro high-throughput microscope (Molecular Devices) with a 20× objective. Four to nine fields were acquired for each well using the YFP filter set. Cells that exhibited the expected localization of the targeted protein were retained for PCR and western blot analysis.
For lower resolution microscopy (×20), cells were either imaged with an ImageXpress micro high-throughput microscope (Molecular Devices) for destruction curves or using a DeltaVision Core microscope (Applied Precision) equipped with a QuantEM:512sc EMCCD camera (Photometrics) and an environmental chamber at 37 • C (Applied Precision) for Fig. 4b . For higher resolution microscopy and molecule counts, cells were imaged using an Intelligent Imaging Innovations confocal spinning-disc microscope equipped with a CSU-X1 head (Yokogawa) and a QuantEM:512sc EMCCD camera (Photometrics). For molecule counts, 50 0.5 µm slices were acquired with a ×60 objective with a 100 ms exposure time (488 nm laser excitation). For correlative studies between Venus-MAD2 foci intensity and the strength of the checkpoint, cells were imaged every 10 min with 15 1 µm slices per acquisition on the same microscope, but using a ×40 objective. In all experiments 10% laser power (Neutral density) was used.
Quantification of fluorescence microscopy data. For cyclin-A2-Venus and cyclin-B1-Venus destruction analysis, fluorescence intensities were measured and analysed using ImageJ software as previously described 44 .
To calculate Venus-MAD2 molecule numbers (Fig. 3f ), integrated fluorescence intensities were measured from the sum of intensity projections of z-sections and correlated to total molecule numbers in a cell obtained by antibody calibration with cell extracts and recombinant MAD2 protein 45 . The method described in ref. 46 was used to determine local fluorescence intensities at kinetochores and local molecule numbers were obtained by using the correlation above. Total fluorescence intensity (F tot ) at a kinetochore was calculated using the following equation:
where F i is the total fluorescence in the inner (kinetochore) circle whose area is A i and F o is the total fluorescence in the outer (local cytoplasm) circle whose area is A o . All local fluorescence intensities were corrected for background and bleaching. Isolated kinetochores from maximum intensity projections were carefully selected after analysing individual z-planes. Only kinetochores around the middle z-section were quantified to minimize differences in fluorescence absorption by the cell.
To evaluate the number of Venus-MAD2-positive kinetochores per cell in different drug treatments, each z-section of individual cells was visually screened for kinetochore-like fluorescence patterns using CENPA-Cerulean as an internal control. The fluorescence of a single kinetochore typically spanned 2-3 z-sections (one z-section brighter than the others). In the case of kinetochore clusters, the number of individual kinetochores was estimated by surface area.
For the quantification of Venus-MAD2 fluorescence in the partial siRNA experiments (Fig. 4c-e ), confocal sections were projected (maximum intensity projection) and total fluorescence intensities were measured when cells finished rounding up (10-20 min after NEBD). Integrated kinetochore intensities of Venus-MAD2 were obtained by thresholding raw images (∼10 min after NEBD) until cytoplasmic signals were completely excluded and measuring the entire area containing the extracted kinetochore signals.
For mitotic profiling in Figs 5g and h, RPE1 CCNB1 Venus/+ knock-in cells were automatically detected in each image using a modified count nuclei journal in MetaXpress and plotted against time. Fig.3c , fixed with methanol and processed for immunofluoresence. Mad2 foci that colocalised with ACA staining were counted (n=20 cells for nocodazole; n=7 cells for Taxol and n=10 cells for DMA) and compared to the data obtained by live-cell imaging (Fig. 3d,e ). Error bars indicate s.d.. and are representative of at least two independent experiments. (e) Quantification of Venus-Mad2 molecules in protein extracts by immunoblotting using an anti-Mad2 antibody and recombinant His 6 -Mad2. Mitotic Venus-Mad2 RPE1 cells were collected by mitotic shake-off after nocodazole treatment, counted and processed for immunoblotting. Protein extracts were prepared from known numbers of cells. Molecular mass markers on the left. (f) Calibration curve for the Mad2 antibody obtained by quantifying band intensities in (e). The dotted line represents the linear regression. The inset graph shows the frequency distribution of Venus-Mad2 fluorescence in cells treated with nocodazole and analyzed by confocal microscopy (n=100 cells). Note that by knowing the mean number and mean fluorescence of Venus-Mad2 molecules per cell we can calculate the mean fluorescence per molecule of Venus-Mad2. (g) A maximum intensity projection of 50 z -sections taken at 0 .5 µm intervals was used to identify individual kinetochores. (h) An inner circle (red) was drawn around the single kinetochore. An outer circle (blue) just around the inner circle was used to measure the local background around the kinetochore. (i) Since kinetochore signals span more than one 0.5 µm z-section, sum intensity projections were used to measure the integrated fluorescence intensity. (j) Equation used to obtain the total fluorescence intensity (Ftot) of a single kinetochore. This takes into account the local background and the respective areas of measurements. Note that all integrated fluorescence intensities were initially corrected for camera noise by subtracting fluorescence intensities of regions adjacent to cells. Scale bar = 10 µm. 
